The PDUFA date on December 22, 2026 is the primary catalyst. Cash runway into 2028 covers launch. The $98.3M term loan adds leverage but extends runway. Monitor FDA decision and any advisory committee outcome.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $15.24entry
- T+1 · 11d ago +0.59%α +0.28% · $15.33
- T+5 · 5d ago +1.71%α −1.58% · $15.50
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Mineralys Therapeutics reported Q3 2026 net loss of $57.3M, wider than the $36.9M loss in Q3 2025, driven by a $27.7M increase in G&A expenses as the company scales pre-commercial operations ahead of the December 22, 2026 PDUFA date for lorundrostat. The NDA review is ongoing and commercial launch preparations are on track. Director Derek DiRocco resigned effective December 31, 2026, with no disagreement stated.
Key Financial Metrics
Key Facts
- Net loss of $57.3M for Q3 2026 vs $36.9M in Q3 2025
- Cash, cash equivalents and investments $624.7M as of Sep 30, 2026
- Senior secured term loan of $98.3M (net) on balance sheet
- PDUFA target date for lorundrostat NDA remains December 22, 2026
- Director Derek DiRocco resigning effective December 31, 2026, no disagreement cited
- 46% of Launch-HTN participants on lorundrostat 50 mg achieved AHA/ACC SBP target of 130 mmHg at Week 12
Financial Impact
Net loss increased 55% YoY to $57.3M; G&A expenses rose 286% to $37.4M; cash burn $31.9M in Q3
Risk Factors
- FDA may not approve lorundrostat by the PDUFA date or at all
- Commercial launch costs are accelerating, widening losses
- Director resignation, though amicable, removes a board member ahead of a key regulatory decision
- Dependence on single product candidate lorundrostat
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001933414-26-000142 |
| Document: mlys-20261029.htm | 0001933414-26-000142 |
| Document: 0001933414-26-000142-index-headers.html | 0001933414-26-000142 |
| Document: 0001933414-26-000142-index.html | 0001933414-26-000142 |
| Document: 0001933414-26-000142.txt | 0001933414-26-000142 |
| 8-K Data (Synthetic) | 0001933414-26-000142 |
Track record
35 reports on MLYS
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +20.97% at T+20 after the Jun 11, 2026 report. 5 of 10 went positive at some point.
Filters
- Nov 8, 20268d ago Press Release Bullish 6/10 Entry $15.81 Now $14.53 −8.10% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Viewing Entry $15.24 Now $14.53 −4.66% settles Dec 4
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $15.99 Now $14.53 −9.13% settles Dec 2
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $18.18 Now $14.53 −20.08% settles Nov 30
- Oct 28, 202619d ago Press Release Bullish 6/10 Entry $21.38 Now $14.53 −32.04% settles Nov 25
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $21.10 Now $14.53 −31.14% settles Nov 18
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $21.10 Now $14.53 −31.14% settles Nov 18
- Oct 19, 202628d ago 8-K Neutral 2/10 Entry $21.58 Now $14.53 −32.67% settles Nov 17
- Oct 13, 20264w ago 144 Neutral 3/10 Entry $20.76 to $16.16 Now $14.53 −30.01% ▼ −22.16% −20.89% vs SPY
- Sep 30, 20266w ago 144 Neutral 3/10 Entry $23.72 to $21.24 Now $14.53 −38.74% ▼ −10.46% −11.16% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers